Orally administered peptides to ameliorate atherosclerosis
AssigneeThe Regents of the University of California
InventorsAlan M. Fogelman, Gattadahalli M. Anantharamaiah, Mohamad Navab
Life of this patent
Estimating the term…
Abstract
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.
Claims83
A peptide that ameliorates a symptom of atherosclerosis, wherein said peptide comprises an amino acid sequence that:
- ranges in length from about 10 to about 30 amino acids;
- comprises at least one class A amphipathic helix;
- comprises at least one “D” amino acid residue;
- protects a phospholipid against oxidation by an oxidizing agent;
- and
- is not the D-18A peptide.
A composition suitable for oral administration that ameliorates a symptom of atherosclerosis, wherein said composition comprises a peptide that is a human apo A-I peptide or an analogue of a human apo A-I peptide wherein said peptide has a first protecting group attached to an amino terminal and a second protecting group attached to a carboxyl terminal and further wherein said peptide comprises a plurality of D amino acid residues.
A method of ameliorating a symptom of atherosclerosis in a mammal, said method comprising administering to said mammal a peptide or a concatamer of a peptide that:
- ranges in length from about 10 to about 30 amino acids;
- comprises at least one class A amphipathic helix;
- comprises at least one “D” amino acid residue;
- protects a phospholipid against oxidation by an oxidizing agent;
- and
- is not the D-18A peptide.
A method of ameliorating a symptom of atherosclerosis, said method comprising orally administering to an organism a composition that comprises a peptide that is a human apo A-I peptide or an analogue of a human apo A-I peptide wherein said peptide has a first protecting group attached to an amino terminal and a second protecting group attached to a carboxyl terminal and further wherein said peptide comprises a plurality of D amino acid residues.
The method of claim 74, wherein said organism is an organism diagnosed as having one or more symptoms of atherosclerosis.
The method of claim 74, wherein said organism is an organism diagnosed as at risk for atherosclerosis.
The method of claim 74, wherein said organism is a human.
The method of claim 74, wherein said organism is non-human mammal.
The method otf claim 74, wherein said first protecting group and said second protecting group are independently selected from the group consisting of an acetyl, a CH3—(CH2)n—CO— where n ranges from 3 to 20, and an amide.
The method of claim 74, wherein said first protectin, group is an acetyl.
The method of claim 74, wherein said second protecting group is an amide.
The method of claim 74, wherein said composition further comprises a pharmaceutically acceptable excipient.
The method of claim 74, wherein said peptide protects a phospholipid from oxidization by an oxidizing agent.
A kit for ameliorating a symptom of atherosclerosis, said kit comprising a container containing a peptide that:
- ranges in length from about 10 to about 30 amino acids;
- comprises at least one class A amphipathic helix;
- comprises at least one D amino acid residue;
- protects a phospholipid against oxidation by an oxidizing agent;
- and
- is not the 18-A peptide.
A kit for ameliorating a symptom of atherosclerosis, said kit comprising a container containing a composition suitable for oral administration that ameliorates a symptom of atherosclerosis, wherein said composition comprises a peptide that is a human apo A-I peptide or an analogue of a human apo A-I peptide, wherein said peptide has a first protecting group attached to an amino terminal and a second protecting group attached to a carboxyl terminal and further wherein said peptide comprises a plurality of D amino acid residues.
Dependencies are inferred from the claim text.